• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

    14.71 -0.68 (-4.39%)
    Streaming Delayed Price Updated: 10:38 AM EST, Jan 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aardvark Therapeutics, Inc. - Common Stock

    News headline image
    Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
    Aardvark to host Investor Webinar with members of the management team, leading key opinion leaders and patient advocates on November 5, 2025 
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
    Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient Population 
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.